Neurocrine Bioscienc (NASDAQ:NBIX) has grabbed attention from the analysts, when it saw a value decrease of -1.11% or -0.82 points in the last trading session to close at $73.01. A total of 2.42 Million shares exchanged hands during the intra-day trade compared with its average trading volume of 1.08 Million shares, while its relative volume stands at 2.29. Neurocrine Bioscienc (NASDAQ:NBIX) has a market cap of $6.84 Billion and the number of outstanding shares have been calculated 93.69 Million.
Shares of Neurocrine Bioscienc (NASDAQ:NBIX) currently have an Average Brokerage Recommendation of 1.19, number of Recs in ABR is 13 while industry rank of the company by ABR is out of 257. Out of the analyst recommendations 6 rate Neurocrine Bioscienc (NASDAQ:NBIX) stock a Buy, 8 rate the stock Outperform, 1 rate Hold, 0 rate Underperform and 0 recommend a Sell.
Taking a glance at where the stock might be directed in the future, on a consensus basis, the sell-side has a 52 week price target of $108.75 on the stock, this valuation is based on 16 number of opinions. The most optimistic analyst sees the stock reaching $162 while the most conventional has $84 target price.
Neurocrine Bioscienc (NASDAQ:NBIX) as of recent trade, has shown weekly downbeat performance of -16.05% which was maintained at -29.12% in 1-month period. During the past three months the stock slid -39.6%, bringing six months performance to -27.03%. Yearly performance of the stock shows a bullish trend of 4.14% while year-to-date (YTD) performance reflected -5.9% negative outlook.
While taking a glance at financials, we can look at a number of key indicators. Neurocrine Bioscienc (NASDAQ:NBIX) has trailing twelve month Return on Assets of 1.2%, which is key indicator of how profitable a company is relative to its total assets. The company currently has a Return on Equity of 2.5% and a Return on Investment of -17.7%. ROI is a performance measure used to evaluate the efficiency of an investment or to compare the efficiency of a number of different investments.
While having a peek at profitability ratios Neurocrine Bioscienc (NASDAQ:NBIX) has trailing twelve month gross margin at 99%, its trailing twelve month operating margin stands at 6.5% whereas its trailing twelve month net profit margin spots at 2.4%.
However looking at valuation ratios the stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 1058.12. The company’s forward price to earnings ratio for next fiscal year is 43.33. Neurocrine Bioscienc (NASDAQ:NBIX)’s price to free cash flow for trailing twelve months is 97.3. Its beta value stands at 0.97.
The company’s quick ratio for most recent quarter is 1.6 along with current ratio for most recent quarter of 1.6. Total debt to equity ratio of the company for most recent quarter is 0.86 whereas long term debt to equity ratio for most recent quarter is 0.